dordaviprone hydrochloride · Chimerix · NDA 219876
Modeyso
Earliest generic entry, as listed
30 Jan 2037
Blocked by patent: US 10172862, US 10369154, US 12102639. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10172862 | use U-4254 | 30 Jan 2037 |
| US 10369154 | use U-4254 | 30 Jan 2037 |
| US 12102639 | use U-4254 | 30 Jan 2037 |
| US 11976068 | product | 1 Mar 2036 |
| US 9265765 | product | 26 Jul 2034 |
| US RE46290 | use U-4254 | 30 Aug 2032 |
| US 9629842 | use U-4254 | 30 Apr 2032 |
Exclusivities · 2 unexpired
| ODE-547 | orphan drug (7 years) | 6 Aug 2032 |
| NCE | new chemical entity (5 years) | 6 Aug 2030 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219876 · 001 · RLD | capsule, oral | EQ 125MG BASE | 30 Jan 2037 |